Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Appl Health Econ Health Policy
.
2020 Feb;18(1):141.
doi: 10.1007/s40258-019-00548-6.
Authors
Renée Else Michels
1
,
Maria De Francesco
2
,
Koshu Mahajan
3
,
Gerald J D Hengstman
4
,
Krijn M H Schiffers
5
,
Sangeeta Budhia
6
,
Gerard Harty
7
,
Marieke Krol
8
Affiliations
1
IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.
2
IQVIA, Real World Insights, Da Vincilaan 7, 1930, Zaventem, Belgium.
3
IQVIA, Real World Insights, Gurgaon, India.
4
Department of Neurology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
5
Merck B.V., Tupolevlaan 41-61, 1119 NW, Schiphol-Rijk, The Netherlands.
6
PAREXEL International, PAREXEL Access Consulting, London, UK.
7
EMD Serono, a business of Merck KGaA, Boston, MA, USA.
8
IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. Marieke.Krol@iqvia.com.
PMID:
31939112
PMCID:
PMC6978442
DOI:
10.1007/s40258-019-00548-6
Abstract
The second author's name should be "Maria De Francesco" rather than "Maria de Fransesco".
Publication types
Published Erratum